Kura Oncology, Inc. (KURA)
| Market Cap | 1.89B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -89.63M |
| Shares Out | 53.08M |
| EPS (ttm) | -1.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $28.59 |
| Previous Close | $29.47 |
| Change ($) | -0.88 |
| Change (%) | -2.99% |
| Day's Open | 29.85 |
| Day's Range | 27.81 - 29.50 |
| Day's Volume | 391,723 |
| 52-Week Range | 9.89 - 43.00 |
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC –
The FDA has designated Breakthrough Therapy status to Kura Oncology Inc's (NASDAQ: KURA) tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for head and neck cancer. The status covers ...
– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations –
SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
– Panel discussion on precision medicine to be hosted by former FDA Commissioner Dr. Scott Gottlieb – – Panel discussion on precision medicine to be hosted by former FDA Commissioner Dr. Scott Gottlieb –
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
Kura Oncology looks an attractive opportunity in the Precision Medicine / Targeted Therapies sector.
SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
– Evidence of biologic activity observed in each dose-escalation cohort treated to date –
Event to follow presentation of preliminary clinical data for menin inhibitor KO-539 at ASH Event to follow presentation of preliminary clinical data for menin inhibitor KO-539 at ASH
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2020 Results - Earnings Call Transcript
SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...
SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer,...
– Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of HNSCC –
– First clinical data from the KOMET-001 study to be presented on December 5, 2020 – – First clinical data from the KOMET-001 study to be presented on December 5, 2020 –
SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. The post Kura Oncology Clears Key Benchmark, Hitting 90-Plus RS Rating appeared first on Investor's...
Kura Oncology (KURA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cance...
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2020 Results - Earnings Call Transcript
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cance...
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
– Oral presentation to highlight clinical data for tipifarnib in HRAS mutant solid tumors, including overall survival data in head and neck squamous cell carcinoma – – Oral presentation to highlight cli...
SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...
SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...
SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2020 Results - Earnings Call Transcript
Kura Oncology is riding the coattails of another clinical-stage biopharmaceutical company.
– Second Fast Track designation for tipifarnib further highlights potential for tipifarnib to address unmet need for patients –
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2019 Results - Earnings Call Transcript
– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success –
Company strengthens leadership team to support pre-commercial efforts and launch optimization Company strengthens leadership team to support pre-commercial efforts and launch optimization
– Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC –
– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma –
Kura Oncology Should Be On Your Radar With Upcoming Presentation For Cancer Study
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2019 Results - Earnings Call Transcript
– Former Biogen senior counsel brings more than 20 years of combined in-house and law firm experience – – Former Biogen senior counsel brings more than 20 years of combined in-house and law firm experie...
– 56% confirmed ORR in 18 efficacy-evaluable HNSCC patients with HRAS mutant variant allele frequency ≥ 20% –
– Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29th –
SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cance...
– Accomplished executive adds extensive experience in launching novel therapies as Company sets sights on commercial readiness – – Accomplished executive adds extensive experience in launching novel the...
– KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction –
– Confirmed objective responses achieved in five of 13 evaluable patients –
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2019 Results - Earnings Call Transcript
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the ... [Read more...]
| Industry Biotechnology | Founded 2014 |
| CEO Troy Wilson | Employees 88 |
| Stock Exchange NASDAQ | Ticker Symbol KURA |
Analyst Forecasts
According to 10 analysts, the average rating for Kura Oncology stock is "Buy." The 12-month stock price forecast is 43.29, which is an increase of 51.42% from the latest price.